| HeartMate Left Ventricular Assist Systems (LVAS) are designed to assist the pumping function of the natural heart's left ventricle in patients with end-stage heart failure. The left ventricle, which supplies oxygenated blood to the body, accounts for about 80% of all heart failure. The HeartMate LVAS is indicated for use as a bridge to cardiac transplantation for patients with non-reversible left ventricular failure who are at risk of imminent death. The HeartMate LVAS allows patients to recover end organ function and improve physical conditioning while waiting for a donor heart to become available. The HeartMate XVE LVAS is also approved for use as Destination Therapy, i.e. LVAS support as an alternative to optimal medical therapy, for end-stage heart failure (ESHF) patients ineligible for heart transplants*.
* NYHA Class IV patients with end-stage left ventricular failure who have received optimal medical therapy for at least 60 of the last 90 days, who have a life expectancy of less than two years, and who are not candidates for cardiac transplantation. |
 |
 |
